Úlehlová, J.; Piskláková, B.; Ivanovová, E.; Procházková, J.; Bradáčová, P.; Kvasnička, A.; Friedecký, D.; Slavík, L.
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients. Diagnostics 2021, 11, 2027.
https://doi.org/10.3390/diagnostics11112027
AMA Style
Úlehlová J, Piskláková B, Ivanovová E, Procházková J, Bradáčová P, Kvasnička A, Friedecký D, Slavík L.
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients. Diagnostics. 2021; 11(11):2027.
https://doi.org/10.3390/diagnostics11112027
Chicago/Turabian Style
Úlehlová, Jana, Barbora Piskláková, Eliška Ivanovová, Jana Procházková, Pavla Bradáčová, Aleš Kvasnička, David Friedecký, and Luděk Slavík.
2021. "Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients" Diagnostics 11, no. 11: 2027.
https://doi.org/10.3390/diagnostics11112027
APA Style
Úlehlová, J., Piskláková, B., Ivanovová, E., Procházková, J., Bradáčová, P., Kvasnička, A., Friedecký, D., & Slavík, L.
(2021). Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients. Diagnostics, 11(11), 2027.
https://doi.org/10.3390/diagnostics11112027